Related Experiment Video

Updated: Jun 12, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.1K

Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study

Reineke A Schoot1, Pieter Taselaar1, Giovanni Scarzello2

  • 1Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Head & Neck
|November 15, 2024
PubMed
Abstract

Insights

Treatment for parameningeal rhabdomyosarcoma (RMS) in children did not improve survival outcomes. Meningeal involvement, tumor site, and age remain key prognostic factors for pediatric rhabdomyosarcoma.

Area of Science:

  • Pediatric Oncology
  • Cancer Research
  • Sarcoma Treatment

Background:

  • Parameningeal (PM) rhabdomyosarcoma (RMS) is associated with poor prognosis.
  • Previous studies indicate unfavorable outcomes for PM RMS.
  • Risk stratification is crucial for managing PM RMS.

Purpose of the Study:

  • To describe treatment and outcomes for pediatric patients with PM RMS.
  • To investigate the prognostic value of risk factors in PM RMS.
  • To evaluate the effectiveness of risk-adapted, multi-modal therapy in PM RMS.

Main Methods:

  • Patients with PM RMS were enrolled in the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study.
  • Treatment involved risk-adapted, multi-modal therapeutic approaches.
  • PM site was scored by originating site and highest risk extension.

Main Results:

  • 381 patients with PM RMS were included in the study.
  • Radiotherapy was administered to 359 patients (77 with surgery).
  • Five-year event-free survival was 60%, and overall survival was 65%.

Conclusions:

  • Outcomes for PM RMS patients have not improved compared to historical data.
  • Rigorous radiotherapy application (94%) did not enhance survival.
  • Meningeal involvement, PM site, and age at diagnosis are significant prognostic factors.
Keywords:
head and neckparameningealpediatricprognostic risk factorsrhabdomyosarcoma

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.4K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.1K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...